Market Place
Sourcing Support
Jacobio`s IND Accept for Ph I/II Trial of BET Inhibitor JAB-8263
02 Jul 2025 //
PR NEWSWIRE
Jacobio Pharma Announces 2024 Annual Results
19 Mar 2025 //
PR NEWSWIRE
Registrational Clinical Data of Glecirasib was Published
06 Jan 2025 //
PR NEWSWIRE
Jacobio Pharma Shares BET Inhibitor Data for Myelofibrosis at ASH
08 Dec 2024 //
PR NEWSWIRE
Jacobio Out-Licenses KRAS And SHP2 Inhibitors To Allist In China
31 Aug 2024 //
PR NEWSWIRE
Jacobio`s SHP2 Plus KRAS G12C Data Presented At ASCO
01 Jun 2024 //
PR NEWSWIRE
Jacobio plans bid for China’s KRAS market with safety edge
02 May 2024 //
PHARMAPHORUM
Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint
30 Apr 2024 //
PR NEWSWIRE
Jacobio: PARP7 Inhibitor, P53 Reactivator Data At AACR 2024
09 Apr 2024 //
PR NEWSWIRE
Jacobio Pharma Announces 2023 Annual Results
28 Mar 2024 //
PR NEWSWIRE
Jacobio Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S.
01 Mar 2024 //
PR NEWSWIRE
Jacobio Announces China CDE Clearance for PIII Trial of KRAS G12C Inhibitor
18 Feb 2024 //
PR NEWSWIRE
Jacobio Presents Results of Glecirasib in Combination with JAB-3312 at ESMO
22 Oct 2023 //
PR NEWSWIRE
Jacobio Announces Breakthrough Therapy Designation from China CDE for KRAS G12C
07 Aug 2023 //
PR NEWSWIRE
Jacobio Pharma to Present Data of Glecirasib in Combination with JAB-3312
20 Jul 2023 //
PR NEWSWIRE
AbbVie sends Chinese biotech`s SHP2 pact back to port
05 Jul 2023 //
FIERCE BIOTECH
Jacobio Receives CDE Approval for Glecirasib`s Pancreatic Cancer Pivotal Study
04 Jul 2023 //
PR NEWSWIRE
Jacobio Pharma Presents Clinical Results of Glecirasib in Colorectal Cancer
29 Jun 2023 //
PR NEWSWIRE
Jacobio announces collaboration to evaluate CD73 monoclonal antibody JAB-BX102
22 Mar 2023 //
PR NEWSWIRE
Jacobio Pharma Announces 2022 Annual Results
22 Mar 2023 //
PR NEWSWIRE
Jacobio to Present Data of Three Studies at the 2023 AACR Annual Meeting
14 Mar 2023 //
PR NEWSWIRE
Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S
08 Jan 2023 //
PR NEWSWIRE
Jacobio to Collaborate with Merck on Trial of JAB-21822 with Cetuximab
12 Oct 2022 //
PRNEWSWIRE
Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822`s PII Study
06 Sep 2022 //
PRNEWSWIRE
Jacobio Pharma begins patient dosing in phase I/IIa trial of CD73 mAb JAB-BX102
05 Sep 2022 //
PHARMABIZ
Jacobio Completes First Patient Dosage of CD73 mAb JAB-BX102 in China
02 Sep 2022 //
PRNEWSWIRE
Jacobio will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822
27 May 2022 //
PRNEWSWIRE
Jacobio JAB-21822 + Cetuximab Completes First Dose of Colorectal Cancer Patient
23 Feb 2022 //
PRNEWSWIRE
Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 from FDA
16 Jan 2022 //
PRNEWSWIRE
Jacobio Receives IND Approval for Combo Therapy of KRAS G12C and Cetuximab Inj
05 Dec 2021 //
ASIAONE
Jacobio Receives IND Approval for Comb. Therapy of KRAS G12C & Cetuximab Inj.
05 Dec 2021 //
PRNEWSWIRE
Jacobio Pharmaceuticals Announces 2021 Interim Results
31 Aug 2021 //
PRNEWSWIRE
Jacobio Announces Strategic Investment in Hebecell to Further Develop iPSC-NK
31 Aug 2021 //
PRNEWSWIRE
Jacobio`s First Patient Dosed in Phase I/II Trial of KRAS G12C Inhibitor
02 Aug 2021 //
PRNEWSWIRE
Jacobio Earns $20M AbbVie Milestone
21 Jun 2021 //
CONTRACTPHARMA
Jacobio Earns $20M AbbVie Milestone
18 Jun 2021 //
CONTRACTPHARMA
Jacobio Announces First Two Patients Dosed in SHP2 Combination Study
18 Jun 2021 //
PRNEWSWIRE
Jacobio Gets US$20 Million Milestone Payment
17 Jun 2021 //
PRNEWSWIRE
